FDA Rejects Regeneron’s Bid to Extend EYLEA HD Dosing Beyond 16 Weeks
April 22, 2025

FDA Rejects Regeneron’s sBLA to Extend EYLEA HD Dosing Interval

Regeneron’s proposal to lengthen EYLEA HD dosing intervals to 24 weeks hits a CRL roadblock.​ The wait for extended treatment…

Thumbnail Article_Article 3
April 5, 2025

Key Retinal Debates Sizzle in APAO-AIOC 2025 India AAO Symposium

Experts grappled with contemporary retinal topics from firstline treatments in PDR, CSC and myopic tractional maculopathy to OCT-A. The sun…

latest posts
FDA Rejects Regeneron’s Bid to Extend EYLEA HD Dosing Beyond 16 Weeks
April 22, 2025

FDA Rejects Regeneron’s sBLA to Extend EYLEA HD Dosing Interval

Thumbnail Article_Article 3
April 5, 2025

Key Retinal Debates Sizzle in APAO-AIOC 2025 India AAO Symposium

Thumbnail article _ 1200x675_FDA Approves Neurotech’s ENCELTO for Treatment of Macular Telangiectasia Type 2
March 7, 2025

FDA Approves Neurotech’s ENCELTO for Treatment of Macular Telangiectasia Type 2 

2
October 19, 2024

AAO 2024 Subspecialty Day Update: Neovascular AMD

Thumbnail_Article Day 3 08
July 26, 2024

New Horizons in Retinopathy of Prematurity Treatment, Tailoring Care for Premature Infants

COVER ART TOC
November 17, 2023

A REVOLUTION in Retinal Therapies: From anti-VEGF to TKIs and gene therapy, cutting-edge innovations are changing the landscape of medical retina

Funny,Halloween,Dog,Wearing,A,Zombie,Bloodshot,Eyes,Glasses.,Isolated
March 30, 2023

Bloodshot Eyes: Cracking the Code of Retinal Vascular Disorders

Close,Up,Of,Eye,Iris,On,Black,Background,,Macro,,Photography
March 10, 2022

The All-Important Macula: E-poster Highlights from RANZCO 2022

Discover our fascinating content at issuu

explore